WO2009158682A3 - Compositions and methods for diagnosing and treating pathogenic disorders - Google Patents

Compositions and methods for diagnosing and treating pathogenic disorders Download PDF

Info

Publication number
WO2009158682A3
WO2009158682A3 PCT/US2009/048965 US2009048965W WO2009158682A3 WO 2009158682 A3 WO2009158682 A3 WO 2009158682A3 US 2009048965 W US2009048965 W US 2009048965W WO 2009158682 A3 WO2009158682 A3 WO 2009158682A3
Authority
WO
WIPO (PCT)
Prior art keywords
bacteria
antigen
pathogenic agent
infective
reaction
Prior art date
Application number
PCT/US2009/048965
Other languages
French (fr)
Other versions
WO2009158682A2 (en
Inventor
D. Tobin Watkinson
Original Assignee
Watkinson D Tobin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watkinson D Tobin filed Critical Watkinson D Tobin
Publication of WO2009158682A2 publication Critical patent/WO2009158682A2/en
Publication of WO2009158682A3 publication Critical patent/WO2009158682A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Abstract

The present invention is a method of detection to identify antigen reactivity between infective agents, e.g., bacteria, viruses, parasites, bacteriophages, spirochetes, microbes and common foods, beverages, inhalants, chemical preparations, perfumes, fragrances, pollens, animal proteins and dander. As a result of the specific identification of the pathogenic agent/antigen reaction, a vaccine can be constructed to eradicate such allergic reaction. The test platform represents a series of impregnated test modules or bioelectric collections containing sample libraries of infective materials which have potential cross reactivity with a human subject's biological fluid sample or response testing using galvanic skin response testing to other methods of electromedicine techniques and reagent and/or filters when needed. Automated sequential retesting or manual biopanning for the positive reactions; allergen/bacteria, bacteria/virus, virus/bacteria, result in the underlying antigen/pathogenic agent reaction. Once such causative infective agent relationship is identified there are several options for vaccine preparation or treatment to reduce or eradicate the identified causative pathogenic agent.
PCT/US2009/048965 2008-06-27 2009-06-26 Compositions and methods for diagnosing and treating pathogenic disorders WO2009158682A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7657108P 2008-06-27 2008-06-27
US61/076,571 2008-06-27

Publications (2)

Publication Number Publication Date
WO2009158682A2 WO2009158682A2 (en) 2009-12-30
WO2009158682A3 true WO2009158682A3 (en) 2010-07-22

Family

ID=41445371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/048965 WO2009158682A2 (en) 2008-06-27 2009-06-26 Compositions and methods for diagnosing and treating pathogenic disorders

Country Status (1)

Country Link
WO (1) WO2009158682A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208877A1 (en) * 2017-05-09 2018-11-15 Yale University Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction
US20190083386A1 (en) * 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002037115A1 (en) * 2000-11-03 2002-05-10 Kenton S.R.L. Detection of infectious agents using antigen mimics
US20050037444A1 (en) * 2001-01-26 2005-02-17 Andreas Meinke Method for identification isolation and production of antigens to a specific pathogen
WO2005037053A2 (en) * 2003-05-23 2005-04-28 Board Of Regents - The University Of Texas System High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002037115A1 (en) * 2000-11-03 2002-05-10 Kenton S.R.L. Detection of infectious agents using antigen mimics
US20050037444A1 (en) * 2001-01-26 2005-02-17 Andreas Meinke Method for identification isolation and production of antigens to a specific pathogen
WO2005037053A2 (en) * 2003-05-23 2005-04-28 Board Of Regents - The University Of Texas System High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HILLER, R. ET AL., THE FASEB JOURNAL, 14 January 2002 (2002-01-14) *

Also Published As

Publication number Publication date
WO2009158682A2 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
Galinska et al. Brucellosis in humans-etiology, diagnostics, clinical forms
DE60130468D1 (en) COMPOSITIONS AND METHODS OF TREATING CHLAMYDIA INFECTIONS
Beltrame et al. Seroprevalence and isolation of Toxoplasma gondii from free-range chickens from Espírito Santo state, southeastern Brazil
EP3750916A3 (en) Anti-dengue virus ns1 protein monoclonal antibodies
RU2010101909A (en) METHOD FOR IDENTIFICATION OR TREATMENT OF REACTION "TRANSPLANT AGAINST THE OWNER"
Ruppach Log10 reduction factors in viral clearance studies
WO2009158682A3 (en) Compositions and methods for diagnosing and treating pathogenic disorders
WO2015027154A3 (en) Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
EA201400113A1 (en) BIOLOGICAL MICROCHIP FOR QUANTITATIVE DETERMINATION OF IMMUNOGLOBULINS OF CLASSES E AND G IN BIOLOGICAL LIQUIDS, METHOD OF ANALYSIS WITH ITS USE AND SET OF REAGENTS, IT'S CHAPTER
Tabar et al. Gammopathy in a Spanish dog infected with Bartonella henselae
WO2021235176A1 (en) Evaluation method for allergen inactivator and evaluation kit for allergen inactivator
Kulpa-Eddy et al. Application of the consistency approach to reduce animal use in vaccine potency testing
Botsios et al. Rapid chemical decontamination of infectious CJD and scrapie particles parallels treatments known to disrupt microbes and biofilms
Kenworthy et al. Field evaluation of a test for praziquantel resistance in Schistosoma sp.
CN109776661A (en) A kind of perlsucht gamma interferon ELISA detection cocktail stimulator antigen
Weltzien et al. Safe cosmetics without animal testing? Contributions of the EU Project Sens-it-iv
Dzikwi et al. Serological surveillance for non-rabies lyssaviruses among apparently healthy dogs in Zaria, Nigeria
CN104922938B (en) A kind of cleaning method of affinity column
Roberts Approaches to Handling High Consequence Pathogens
Igolkin et al. Virucidal Activity of Different Disinfectants Against the African Swine Fever Virus
Mirahmadi et al. Determination of the prevalence and type of plasmodium in mosquitoes present in the city of Nik Shahr, Southern Sistan and Baluchestan Province, IR Iran, by Multiplex Nested-PCR
Wood Bashing botulism: scientists sleuth world's most powerful toxins
MY187887A (en) Strongyloides stercoralis protein and/or corresponding dna and rna sequences for application in diagnosis
RU2638811C1 (en) Method for feces biological material sampling for lamblia cysts and cryptosporidia oocysts determination
Aprotosoaei Preliminary investigations in the potential use of dye-ligands to bind biological macromolecules

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09771213

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09771213

Country of ref document: EP

Kind code of ref document: A2